CDMO Blog

close

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies?
5 Considerations for Scaling-Up PSC-Derived Cell Therapies
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant
What is a Bioreactor and How is it Used in Cell and Gene Therapy?
03 Aug 2021

CCRM Collaborates To Tighten Timelines and Prepare Nkarta for IND Filing

CCRM works with customers in a collaborative manner to enable them to ...

27 Jul 2021

3 Ways Your CDMO Can Help You Avoid Supply Chain Problems

The COVID-19 pandemic has significantly disrupted supply chains and pr...

11 Dec 2020

4 Tips from the Experts: How to Tighten Your Timeline from Development to Trial

Responsibly moving a cell or gene therapy forward as quickly as possib...

01 Dec 2020

3 Considerations When Developing Your LVV Program

If you are looking to get a lentiviral vector (LVV) program off the gr...

12 Aug 2020

CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference)

Outsourcing to a contract development and manufacturing organization (...

10 Jan 2020

Road to success: Understanding Good Laboratory Practice for cell and gene therapies

Good Laboratory Practice (GLP) studies are essential for generating no...

Tell us what you thought about this post.